[go: up one dir, main page]

AR065932A1 - Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas - Google Patents

Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas

Info

Publication number
AR065932A1
AR065932A1 ARP080101389A ARP080101389A AR065932A1 AR 065932 A1 AR065932 A1 AR 065932A1 AR P080101389 A ARP080101389 A AR P080101389A AR P080101389 A ARP080101389 A AR P080101389A AR 065932 A1 AR065932 A1 AR 065932A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
cycloalkyl
aryl
different way
Prior art date
Application number
ARP080101389A
Other languages
English (en)
Original Assignee
Anesini Claudia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anesini Claudia filed Critical Anesini Claudia
Publication of AR065932A1 publication Critical patent/AR065932A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Su uso como medicamentos y composiciones farmacéuticas. Reivindicacion 1: Un compuesto de la formula (1) en la que: X, Y de igual o diferente modo -C(R3)(R4)-, -(C=O)-, -(C=S), en la que al menos uno de X o Y es -(C=O)- o -(C=S)-; pero ambos nopueden ser simultáneamente -(C=O)- o -(C=S)-; o X e Y juntos son C(R3)=C(R3); R hidrogeno, alquilo (C1-8), halogenoalquilo (C1-5), (CR5R6)m-O(R7), alquiloxi(C1-3)-alquileno(C1-3, arilo, heterociclo, alquilen(C1-4)-arilo, alquilen(C1-4)-heteroarilo,alquilen(C1-4)-cicloalquilo (C5-12), en los que el cicloalquilo, arilo, heterociclo o heteroarilo pueden estar sustituidos una más veces con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6),alquilo (C1-6), halogenoalquilo (C2-4), O-halogenoalquilo(C2-4), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo(C3-8), alquinilo (C2-6), alquilen(C0-8)-arilo, O-alquilen(C0-8)-arilo, S-arilo, alquilen(C0-8)-heteroarilo, N-(R5)(R6), SO2-CH3,SO2-NH2, SF5, COOH, COO-alquilo(C1-6), CON(R5)(R6), N(R5)CO(R6), N(R5)SO2(R6), CO(R5), (CR5R6)m'-O(R7), O-CO-N(R5)(R6), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R5)(R6), en los que el arilo yheteroarilo pueden estar a su vez sustituidos una o más veces con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo(C3-8),alquinilo (C2-6), N(R8)(R9), SO2-CH3, SF5, COOH, COO-alquilo(C1-6), CON(R8)(R9), N(R8)CO(R9), N(R8SO2(R9), CO(R8), (CR8R9)m''-O(R10), O-CO-N(R8)(R9), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R8)(R9); m, m', m'' 0, 1, 2, 3, 4, 5, 6; R5, R6, R7, R8, R9, R10 de igual o diferente modo hidrogeno, alquilo (C1-8); o -(C=O)-NR1aR2a; o -(C=O)-O-R1b; o Ry X para X = -C(R3)(R4)- forman un sistema anular monocíclico, de 4 a 7 miembros, saturadoso parcialmente insaturado o un sistema anular bibíblico, de 8 a 14 miembros, saturado o parcialmente insaturado, cuyos miembros individuales de los sistemas anulares se pueden sustituir por uno a tres átomos o grupos de átomos de la serie -CHR11-, -CR11R12-, -(C=R11)-, =C(R11)-, -NR11-, -C(=O)-, -O-, -S-, -SO-, -SO2-, con la condicion de que dos unidades de la serie -O-, -S-, -SO-, -SO2- no pueden ser adyacentes; R11, R12 de igual o diferente modo hidrogeno, alquilo (C1-6), arilo, cicloalquilo(C3-12), alquilen(C1-4)-arilo, alquilen(C1-3)-cicloalquilo(C3-12); en los que el arilo o cicloalquilo pueden estar sustituidos con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6),halogenoalquilo(C2-4), O-halogenoalquilo(C2-4), alquenilo (C2-6), alquinilo (C2-6), N(R13)(R14), SO2-CH3, SO2-NH2, SF5, COOH, COO-alquilo(C1-6), CON(R13)(R14), N(R13)CO(R14), N(R13)SO2(R14), CO(R13), (CR13R14)n-O(R15), O-CO-N(R13)(R14), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R13)(R14); n 0, 1, 2, 3, 4, 5, 6; R13, R14, R15 de igual o diferente modo hidrogeno, alquilo (C1-8); R1, R1a, R1b de igual o diferente modo alquilo (C5-16), CH2-arilo, alquilen(C1-2)-heteroarilo, CH2-cicloalquilo(C5-12), en los que el arilo, heteroarilo o cicloalquilo pueden estar sustituidos una o más veces con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6), halogenoalquilo (C2-4), O-halogenoalquilo(C2-4), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo(C3-8), alquinilo (C2-6), alquilen(C0-8)-arilo, O-alquilen(0-8)-arilo, S-arilo, alquilen(C0-8)-heteroarilo,N(R16)(R17), SO2-CH3, SO2-NH2, SF5, COOH, COO-alquilo(C1-6), CON(R16)(R17), N(R16)CO(R17), N(R16)SO2(R17), CO(R16), (CR16R17)o-O(R18), O-CO-N(R16)(R17), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R16)(R17), en los que el arilo o heteroarilo a su vez pueden estar sustituidos una o más veces con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6), alquenilo (C2-6), cicloalquilo(C3-8), O-cicloalquilo(C3-8), alquinilo (C2-6), N(R19)(R20), SO2-CH3, SF5, COOH, COO-alquilo(C1-6), CON(R19)(R20), N(R19)CO(R20), N(R19)SO2(R20), CO(R19), (CR19R20)o'-O(R21), O-CO-N(R19)(R20), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R19)(R20); o, o' 0, 1, 2, 3, 4, 5, 6; R16, R17, R18, R19, R20, R21 de igual o diferente modo hidrogeno, alquilo (C1-8); o un radical de formula (2), con W -C(R28)(R29)-, -C(R28)(R29)-C(R28a)(R29a)-, -C(R28)(R29)-O-; R22, R23, R24, R25, R26, R27, R28, R29, R28a, R29a de igual o diferente modo hidrogeno, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, SF5, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6), halogenoalquilo (C2-4), O-halogenoalquilo(C2-4), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo(C3-8), cicloalquenilo (C3-8), alquinilo (C2-6), N(R30)(R31), SO2-CH3, COOH, COO-alquilo(C1-6), CON(R30)(R31), N(R30)CO(R31), N(R30)SO2(R31), CO(R30), (CR30R31)p-O(R32), O-CO-N(R30)(R31), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R30)(R31); p 0, 1, 2, 3, 4, 5, 6; R30, R31, R32 de igual o diferente modo hidrogeno, alquilo (C1-6); o R22 y R28 o R23 y R29 junto con losátomos de carbono que los llevan forman un sistema anular monocíclico, de 5 o 6 miembros, saturado, parcialmente insaturado o aromático, cuyos miembros individuales se pueden sustituir por -CHR33-, -CR33R34-, =(C-R33)-; o R24 y R26 o R25 y R27 juntocon los átomos de carbono que los llevan forman un sistema anular monocíclico, de 5 o 6 miembros, saturado, parcialmente insaturado o aromático, cuyos miembros individuales se pueden sustituir por -CHR33-, -CR33R34-, =(C-R33)-; R33, R34 de igual odiferente modo F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, SF5, O-alquilo(C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo(C1-6), alquilo (C1-6), halogenoalquilo (C2-4)-, O-halogenoalquilo(C2-4), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo (C3-8),alquinilo (C2-6), N-(R35)(R36), SO2-CH3, COOH, COO-alquilo(C1-6), CON(R35)(R36), N(R35)CO(R36), N(R35)SO2(R36), CO(R35), CR35R36)q-O(R37), O-CO-N(R35)(R36), O-CO-alquilen(C1-6)-CO-O-alquilo(C1-6), O-CO-alquilen(C1-6)-CO-OH, O-CO-alquilen(C1-6)-CO-N(R35)(R36); q 0, 1, 2, 3, 4, 5, 6; R35, R36, R37 de igual o diferente modo hidrogeno, alquilo (C1-6); R2, R2a de igual o diferente modo hidrogeno, alquilo (C1-8); R3, R4 de igual o diferente modo hidrogeno, alquilo (C1-6), bencilo; las formastautomeras del compuesto y las sales fisiologicamente toleradas del mismo; con la condicion de que R1 no es pentilo, CH2-fenilo, -CH2-(2-Cl-fenilo), cilohexilo, -(2-metilciclohexilo) si X = CH2, Y = CO, R = metilo, R2 = H.
ARP080101389A 2007-04-05 2008-04-03 Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas AR065932A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07007161 2007-04-05

Publications (1)

Publication Number Publication Date
AR065932A1 true AR065932A1 (es) 2009-07-08

Family

ID=38169713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101389A AR065932A1 (es) 2007-04-05 2008-04-03 Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas

Country Status (20)

Country Link
US (1) US8735437B2 (es)
EP (1) EP2144885B1 (es)
JP (1) JP2010523503A (es)
KR (1) KR20090126293A (es)
CN (1) CN101646655A (es)
AR (1) AR065932A1 (es)
AU (1) AU2008235066A1 (es)
BR (1) BRPI0809693A2 (es)
CA (1) CA2682875A1 (es)
CL (1) CL2008000981A1 (es)
CO (1) CO6220934A2 (es)
IL (1) IL201255A0 (es)
MA (1) MA31296B1 (es)
MX (1) MX2009010485A (es)
NZ (1) NZ580127A (es)
RU (1) RU2009140761A (es)
TW (1) TW200904804A (es)
UY (1) UY31001A1 (es)
WO (1) WO2008122352A1 (es)
ZA (1) ZA200906211B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013048982A1 (en) * 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8933235B2 (en) 2011-09-30 2015-01-13 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
EP2847174B1 (en) 2012-04-03 2017-05-17 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase
EP2844643B1 (en) * 2012-04-03 2016-11-30 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
AR102942A1 (es) 2014-12-11 2017-04-05 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de cinco miembros c-n-conectados, como plaguicidas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03227976A (ja) * 1990-02-01 1991-10-08 Otsuka Chem Co Ltd イミダゾリジン―２―オン誘導体
JP3227976B2 (ja) 1993-02-26 2001-11-12 松下電器産業株式会社 光学的情報記録部材、記録再生方法、及び記録再生装置
JP3947283B2 (ja) 1997-11-19 2007-07-18 株式会社堀場製作所 イプロジオン及びその代謝物のハプテン化合物、抗体及び測定方法
EP1282622B1 (en) * 2000-05-18 2003-09-17 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US20060211755A1 (en) 2003-03-31 2006-09-21 Eli Lilly And Company Patent Division 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
EP1613608A1 (en) 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Also Published As

Publication number Publication date
CN101646655A (zh) 2010-02-10
AU2008235066A1 (en) 2008-10-16
CA2682875A1 (en) 2008-10-16
WO2008122352A1 (de) 2008-10-16
BRPI0809693A2 (pt) 2014-10-07
MA31296B1 (fr) 2010-04-01
TW200904804A (en) 2009-02-01
EP2144885B1 (de) 2016-06-29
UY31001A1 (es) 2008-11-28
NZ580127A (en) 2011-03-31
EP2144885A1 (de) 2010-01-20
RU2009140761A (ru) 2011-05-10
MX2009010485A (es) 2009-10-19
US8735437B2 (en) 2014-05-27
US20100105719A1 (en) 2010-04-29
KR20090126293A (ko) 2009-12-08
CL2008000981A1 (es) 2008-10-10
ZA200906211B (en) 2010-05-26
CO6220934A2 (es) 2010-11-19
JP2010523503A (ja) 2010-07-15
IL201255A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
AR065932A1 (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR079510A1 (es) Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central.
AR068639A1 (es) Derivados de biarilo
AR079448A1 (es) Inhibidores de la esfingosina quinasa
HRP20150977T1 (hr) C-28 amidi modificiranih derivata c-3 betulinske kiseline kao inhibitori sazrijevanja hiv-a
CL2008003384A1 (es) Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR082102A1 (es) Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
ES2222336T3 (es) Inhibidores de girasas y sus usos.
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
AR065266A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
AR040514A1 (es) Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR079483A1 (es) Inhibidores heterociclicos de la esfingosina quinasas, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en enfermedades hiperproliferativas y/o inmunologicas.
AR060945A1 (es) Prolinamidas sustituidas y su uso como medicamentos
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR079967A1 (es) Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos
AR056051A1 (es) Formulaciones solidas que contienen sulfonamidas
AR051984A1 (es) Compuestos heterociclicos como inhibidores del factor viia

Legal Events

Date Code Title Description
FB Suspension of granting procedure